Join
Live feed
·
PRReleasevia Quantisnow
Stealth BioTherapeutics Corp. ADS logo

STEALTH BIOTHERAPEUTICS ANNOUNCES DATA FROM RECLAIM-2 PHASE 2 TRIAL OF ELAMIPRETIDE IN GEOGRAPHIC ATROPHY

ByQuantisnow·Wall Street's wire, on your screen.
MITO· Stealth BioTherapeutics Corp. ADS
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MITO (Stealth BioTherapeutics Corp. ADS) and more on Quantisnow.